E
ABCL icon

Ergoteles’s AbCellera Biologics ABCL Stock Holding History

Ergoteles’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-418,902
Closed -$2.71M – 23
2023
Q2 		$2.71M Buy
418,902
+383,854
+1,095% +$2.62M 0.13% 201
2023
Q1 		$264K Buy
+35,048
New +$318K 0.01% 929
2021
Q4 		– Sell
-331,414
Closed -$6.64M – 1199
2021
Q3 		$6.64M Buy
331,414
+148,078
+81% +$2.62M 0.24% 114
2021
Q2 		$4.03M Buy
+183,336
New +$5.06M 0.09% 258

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ergoteles's ABCL Position: Q3 2023 in Review

Ergoteles sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 418,902 shares — an estimated $2.71M sold.

Ergoteles first reported a position in ABCL in Q2 2021 and held it in 4 quarters. The position peaked at $6.64M in Q3 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

  • Ergoteles reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 418,902 AbCellera Biologics shares in Q3 2023, an estimated $2.71M.
  • Ergoteles first reported a position in AbCellera Biologics in Q2 2021 and held it in 4 quarters.
  • Ergoteles's AbCellera Biologics position peaked at $6.64M in Q3 2021.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.